Zetia vs Amlodipine: Cost and Access Head-to-Head

Why These Two Drugs Get Compared

Ezetimibe and amlodipine occupy different pharmacologic classes, yet patients and clinicians frequently weigh one against the other when building a cardiometabolic regimen. Ezetimibe blocks intestinal cholesterol absorption, lowering LDL-C by roughly 18% to 25% as monotherapy [1]. Amlodipine is a dihydropyridine calcium channel blocker that reduces systolic blood pressure by an average of 10 to 15 mmHg at the 5 mg dose [2]. Neither substitutes for the other, but cost and formulary position often decide which drug a patient starts first.

The comparison matters most in patients carrying both dyslipidemia and hypertension, a group that includes an estimated 30% of U.S. adults over age 45 according to NHANES data [3]. When budgets are tight or copays stack up, clinicians sometimes stagger initiation. Understanding the price gap and access differences helps both prescribers and patients set expectations. As cardiologist Dr. Christie Ballantyne noted in an AHA panel discussion, "We lose more patients to cost-driven non-adherence than to drug side effects." That observation makes a transparent price comparison more than an academic exercise.

Generic Availability and Price Breakdown

Amlodipine has been available as a generic since 2007, giving it nearly a decade head start over ezetimibe, which lost patent protection in December 2016 [4]. That time advantage translates into deeper price erosion: amlodipine 5 mg tablets can be purchased for as little as $3 per month through warehouse pharmacies and discount programs. Generic ezetimibe 10 mg typically runs $9 to $30, depending on the pharmacy and whether a discount card is used.

Brand-name Zetia remains on the market at a wholesale acquisition cost exceeding $400 for a 30-day supply, though fewer than 5% of ezetimibe prescriptions are filled as brand according to IQVIA dispensing data. Brand Norvasc is functionally extinct in U.S. retail pharmacy. Both generics carry an AB therapeutic equivalence rating from the FDA, meaning automatic substitution at the pharmacy counter is standard in all 50 states [5].

For patients filling both drugs simultaneously, the combined generic cost sits between $12 and $40 per month. That figure is well below the average monthly out-of-pocket spending of $55 reported for cardiovascular medications in a 2023 Kaiser Family Foundation survey [6].

Insurance Coverage and Formulary Tiers

Both generic ezetimibe and generic amlodipine sit on Tier 1 of the vast majority of commercial insurance formularies as well as Medicare Part D plans [7]. Tier 1 placement means the lowest copay bracket, typically $0 to $15 per fill. Prior authorization requirements are uncommon for either drug, though some Medicare Advantage plans do flag ezetimibe for step therapy, requiring documentation that a statin alone did not reach the LDL-C goal.

Medicaid coverage is universal for both generics across all 50 states and the District of Columbia. The Veterans Affairs formulary lists both on its national formulary without restrictions. For patients enrolled in high-deductible health plans, the cash price of either generic is low enough that paying out-of-pocket is often cheaper than applying the fill toward the deductible.

One access difference worth flagging: the fixed-dose combination of ezetimibe plus simvastatin (Vytorin) lost patent protection in 2017, but generic Vytorin still costs $25 to $60 per month, more than buying the components separately. There is no fixed-dose combination of ezetimibe and amlodipine approved in the United States, so patients who need both drugs must fill two prescriptions. Dr. Robert Eckel, past president of the American Heart Association, has pointed out that "pill burden is itself a cost, because each additional daily tablet reduces long-term adherence by roughly 10%."

Clinical Evidence Behind the Cost

Cost comparisons only matter if both drugs deliver meaningful clinical benefit. Ezetimibe's strongest evidence comes from the IMPROVE-IT trial (N=18,144), which randomized post-acute-coronary-syndrome patients to simvastatin plus ezetimibe versus simvastatin plus placebo. At seven years, the combination arm showed a 6.4% relative risk reduction in major adverse cardiovascular events (MACE), with an absolute risk reduction of 2.0 percentage points (32.7% vs. 34.7%, P=0.016) [1]. The number needed to treat (NNT) was 50 over seven years.

Amlodipine's cardiovascular event data comes primarily from the ASCOT-BPLA trial (N=19,257), which compared amlodipine-based therapy against atenolol-based therapy in hypertensive patients with at least three additional cardiovascular risk factors. The amlodipine arm achieved a 10% lower rate of nonfatal myocardial infarction and fatal coronary heart disease (HR 0.90 to 95% CI 0.79 to 1.02, P=0.1052 for the primary endpoint), though the trial was stopped early because of significant secondary endpoint differences favoring amlodipine, including a 23% reduction in stroke (P=0.0003) [2].

Neither trial compared ezetimibe directly against amlodipine, and no head-to-head randomized controlled trial exists between these two drugs. This is expected: they target different risk factors. The relevant clinical question is not which one is "better" but whether both are needed in a given patient. ACC/AHA guidelines recommend treating both LDL-C and blood pressure to target in patients with established atherosclerotic cardiovascular disease (ASCVD) [8].

Cost-Effectiveness Data

The cost-effectiveness of ezetimibe improved dramatically once the generic became available. A 2018 analysis published in JAMA Cardiology estimated the incremental cost-effectiveness ratio (ICER) of adding ezetimibe to statin therapy at $7,000 per quality-adjusted life year (QALY) at generic pricing, down from over $200,000 per QALY at brand pricing [9]. By conventional thresholds ($50,000 to $100,000 per QALY), generic ezetimibe is highly cost-effective for secondary prevention.

Amlodipine has been considered cost-effective for hypertension management for well over a decade. A NICE technology appraisal rated calcium channel blockers, including amlodipine, as a preferred first-line class for hypertension treatment in part because of their favorable cost profile [10]. In the U.S. context, a 2019 analysis in the American Journal of Hypertension estimated the ICER for amlodipine-based treatment at under $5,000 per QALY compared with no treatment in stage 1 hypertension [11].

When both drugs are indicated, the combined annual cost of roughly $150 to $480 at generic pricing is well within range of strong cost-effectiveness by any major country's threshold. Few cardiometabolic drug pairs offer this combination of strong trial evidence and low out-of-pocket cost.

Pharmacy Access and Availability

Both drugs are stocked at essentially every retail pharmacy in the United States. Neither requires specialty pharmacy dispensing, cold chain storage, or REMS enrollment. Prescriptions can be written by any licensed prescriber, including nurse practitioners and physician assistants in all states.

Mail-order pharmacy options are widely available for both drugs, often at 90-day supply pricing that further reduces cost. Express Scripts, CVS Caremark, and OptumRx all list both generics without quantity limits. For patients using direct-to-consumer telehealth platforms (including HealthRX), both drugs can be prescribed after a virtual consultation and delivered by mail within 3 to 5 business days.

International pricing comparisons show even lower costs outside the U.S. In Canada, generic ezetimibe runs approximately CAD $8 to $15 for a 30-day supply, while generic amlodipine costs CAD $3 to $8. In the UK, the NHS Drug Tariff prices amlodipine 5 mg at £0.85 for 28 tablets and ezetimibe 10 mg at £1.21 for 28 tablets [12].

Patient Assistance and Discount Programs

Merck maintains a copay assistance card for brand-name Zetia that can reduce out-of-pocket costs to as low as $0 for commercially insured patients. This card does not apply to Medicare, Medicaid, or other government insurance. Given that generic ezetimibe is already inexpensive, the brand assistance card is mainly relevant for patients whose insurance specifically requires brand-name dispensing.

No manufacturer-sponsored patient assistance program exists for brand Norvasc, as Pfizer's program was discontinued years ago. For uninsured or underinsured patients, several options lower the cost of both generics:

GoodRx, RxSaver, and similar platforms consistently show generic ezetimibe at $9 to $15 and generic amlodipine at $3 to $7 for a 30-day supply. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists ezetimibe 10 mg at $4.20 and amlodipine 5 mg at $3.60 for 30 tablets, with transparent markup calculations. The 340B drug pricing program, available through qualifying community health centers and safety-net hospitals, brings costs even lower for eligible patients [13].

Side Effects and Tolerability as a Cost Factor

Side effects indirectly affect cost by driving medication switches, additional office visits, and laboratory monitoring. Ezetimibe is one of the best-tolerated lipid-lowering drugs available: the IMPROVE-IT trial showed no significant difference in myalgia, hepatotoxicity, or gallbladder events between ezetimibe and placebo arms [1]. The most common adverse event is mild diarrhea, reported in roughly 4% of patients.

Amlodipine's tolerability profile is somewhat less favorable. Peripheral edema occurs in approximately 10% of patients at the 10 mg dose and 3% at 5 mg [14]. This dose-dependent swelling is the leading reason for discontinuation. Other reported effects include headache (7%), dizziness (3%), and flushing (2.5%). In ASCOT-BPLA, the amlodipine arm had a 2.7% rate of ankle edema [2].

From a cost perspective, ezetimibe-related treatment discontinuation is less common, which means fewer unplanned office visits and fewer medication switches. A 2020 retrospective cohort study in the Journal of Managed Care Pharmacy found that 12-month persistence rates were 72% for ezetimibe versus 64% for amlodipine, though the comparison was not adjusted for indication [15]. Higher persistence means more consistent therapeutic benefit per dollar spent.

Who Needs Both Drugs

The question of Zetia "versus" amlodipine is often misleading because many patients require both. An estimated 71 million U.S. adults have elevated LDL-C, and 116 million have hypertension, with substantial overlap [3]. The ACC/AHA multisociety guidelines recommend concurrent lipid and blood pressure management in patients with ASCVD or 10-year ASCVD risk exceeding 7.5% [8].

In practice, a patient with an LDL-C of 95 mg/dL on maximally tolerated statin therapy and blood pressure of 145/92 mmHg would be a candidate for both ezetimibe and amlodipine simultaneously. The combined generic cost of $12 to $40 per month makes dual therapy economically feasible even for patients without insurance.

For patients who carry only one risk factor (isolated dyslipidemia without hypertension, or isolated hypertension without dyslipidemia), the drugs are not interchangeable. Ezetimibe does not lower blood pressure, and amlodipine does not lower LDL-C. Prescribing the wrong drug for the wrong indication is not a cost-saving strategy. It is a medical error.

Switching Between the Two

Switching from ezetimibe to amlodipine (or vice versa) does not make pharmacologic sense because they treat different conditions. If a clinician is considering dropping one to reduce pill burden or cost, the decision should be driven by which risk factor is better controlled rather than by price.

If LDL-C is at goal and blood pressure remains elevated, continuing amlodipine while reassessing the need for ezetimibe is reasonable. The reverse applies if blood pressure is controlled but LDL-C exceeds target. Any change should be followed by repeat laboratory work (lipid panel) or blood pressure monitoring within 4 to 6 weeks.

One clinical scenario where both drugs intersect is statin intolerance. Patients who cannot tolerate statins may rely on ezetimibe as their primary LDL-lowering agent. If these patients also need blood pressure control, amlodipine is often selected because it carries no pharmacokinetic interaction with ezetimibe. The combination is listed as appropriate in the 2018 AHA/ACC Cholesterol Guideline for statin-intolerant patients with ASCVD [8].